First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

MLA

Ying Liu, et al. “First-Line Treatment with Camrelizumab plus Famitinib in Advanced or Metastatic NSCLC Patients with PD-L1 TPS ≥1%: Results from a Multicenter, Open-Label, Phase 2 Trial.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 2, Feb. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2023-007227.

APA

Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, Caigang Liu, Xicheng Wang, Sheng Hu, Yufeng Cheng, Yueyin Pan, Shegan Gao, Yalun Li, Bao-Hui Han, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Yongzhong Luo, … Xinfeng Yang. (2024). First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal for ImmunoTherapy of Cancer, 12(2). https://doi.org/10.1136/jitc-2023-007227

Chicago

Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, et al. 2024. “First-Line Treatment with Camrelizumab plus Famitinib in Advanced or Metastatic NSCLC Patients with PD-L1 TPS ≥1%: Results from a Multicenter, Open-Label, Phase 2 Trial.” Journal for ImmunoTherapy of Cancer 12 (2). doi:10.1136/jitc-2023-007227.